Scholarlink

Background <p>Diabetic peripheral neuropathy (DPN) is a severe diabetic complication with complex pathogenesis. Hyperphosphorylation of tau (p-tau) and neuroinflammation are tightly associated with DPN pathology, although the underlying mechanisms remain obscure.</p> Methods <p>Phosphoproteomics assay with biological verification was performed against the sciatic nerve (SN) tissues from DPN patients and normal individuals to explore the key phosphoprotein(s) involved in DPN pathology. Based on these findings, biological assays including in vivo phosphoprotein-knockdown were then carried out to verify the determined phosphoprotein-mediated mechanisms in DPN pathology against the SN tissues/dorsal root ganglion (DRG) of the model mice.</p> Results <p>Protein phosphatase Mg²⁺/Mn²⁺ dependent 1&#xa0;A (PPM1A) enzyme activity was abnormally reduced in both DPN patients and model mice. Treatment with Miltefosine (MF), a PPM1A activator, effectively improved the DPN-like pathology in mice. PPM1A dysfunction aggravates DPN pathology through NF-κB/NLRP3/p-tau axis involving Schwann cell/DRG neuron crosstalk.</p> Conclusion <p>Our results highlight the close linkage of PPM1A dysfunction to DPN pathology and suggest that pharmacological activation of PPM1A is a potential therapeutic tactic for DPN, while MF shows promise as a valuable drug lead compound against DPN.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

PPM1A dysfunction aggravates DPN pathology through NF-κB/NLRP3/p-tau axis involving Schwann cell/DRG neuron crosstalk

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月7日

查看全文
  • Nixue Song,
  • Yun Ling,
  • Fan Zhou,
  • Jianqiao Fang,
  • Yuanji Zhao,
  • Tong Zhao,
  • Jiaying Wang,
  • Xu Shen

摘要

Background

Diabetic peripheral neuropathy (DPN) is a severe diabetic complication with complex pathogenesis. Hyperphosphorylation of tau (p-tau) and neuroinflammation are tightly associated with DPN pathology, although the underlying mechanisms remain obscure.

Methods

Phosphoproteomics assay with biological verification was performed against the sciatic nerve (SN) tissues from DPN patients and normal individuals to explore the key phosphoprotein(s) involved in DPN pathology. Based on these findings, biological assays including in vivo phosphoprotein-knockdown were then carried out to verify the determined phosphoprotein-mediated mechanisms in DPN pathology against the SN tissues/dorsal root ganglion (DRG) of the model mice.

Results

Protein phosphatase Mg²⁺/Mn²⁺ dependent 1 A (PPM1A) enzyme activity was abnormally reduced in both DPN patients and model mice. Treatment with Miltefosine (MF), a PPM1A activator, effectively improved the DPN-like pathology in mice. PPM1A dysfunction aggravates DPN pathology through NF-κB/NLRP3/p-tau axis involving Schwann cell/DRG neuron crosstalk.

Conclusion

Our results highlight the close linkage of PPM1A dysfunction to DPN pathology and suggest that pharmacological activation of PPM1A is a potential therapeutic tactic for DPN, while MF shows promise as a valuable drug lead compound against DPN.